2026-09-21T10:35:46Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/297332022-01-28T21:49:51Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Fiona Murray.
Yeyinmen, Ali, 1971-
Massachusetts Institute of Technology. Management of Technology Program.
Management of Technology Program.
Sloan School of Management
2006-03-24T16:20:24Z
2006-03-24T16:20:24Z
2003
2003
http://hdl.handle.net/1721.1/29733
54040122
Thesis (S.M.M.O.T.)--Massachusetts Institute of Technology, Sloan School of Management, Management of Technology Program, 2003.
Includes bibliographical references (leaves 58-59).
The importance of "star scientists" in new biotechnology venture formation has been studied by many scholars. However, it is not clear to degree to which their involvement leads to a successful venture. This study examines the importance of the Scientific Advisory Board (SAB), management and venture capital firms during new biotechnology venture creation. In particular, this study has determined if MIT and MIT-Harvard licensed technology companies are able to attract SAB members from top institutions, Board of Directors and CEOs from top pharmaceutical and biotechnology companies as well as top-tier venture capital firms, compared to other biotechnology start-ups in Massachusetts. The results of the study confirm that MIT-Harvard licensed technology companies are able to attract top tier people and venture capital investment during an economic boom as well as the downturn, and this reinforces the proposition that firms are "born" great, rather then achieve greatness at least in terms of the constellation of people who join the firm.
by Ali Yeyinmen.
S.M.M.O.T.
59 leaves
2225612 bytes
2225420 bytes
application/pdf
application/pdf
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Management of Technology Program.
Biotechnology : are firms born great or can you build greatness?
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="dc5c8495-fd19-4f04-b521-b3705dcddf5b">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Biotechnology : are firms born great or can you build greatness?</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2003</PublicationDate>
<Authors>
<Author>
<DisplayName>Yeyinmen, Ali, 1971-</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Management of Technology Program.</Keyword>
<Abstract>The importance of "star scientists" in new biotechnology venture formation has been studied by many scholars. However, it is not clear to degree to which their involvement leads to a successful venture. This study examines the importance of the Scientific Advisory Board (SAB), management and venture capital firms during new biotechnology venture creation. In particular, this study has determined if MIT and MIT-Harvard licensed technology companies are able to attract SAB members from top institutions, Board of Directors and CEOs from top pharmaceutical and biotechnology companies as well as top-tier venture capital firms, compared to other biotechnology start-ups in Massachusetts. The results of the study confirm that MIT-Harvard licensed technology companies are able to attract top tier people and venture capital investment during an economic boom as well as the downturn, and this reinforces the proposition that firms are "born" great, rather then achieve greatness at least in terms of the constellation of people who join the firm.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>